3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Mouth Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Breast Neoplasms
2
Urinary Tract Infections
1
Tongue Neoplasms
1
Tobacco Use Disorder
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Mouth Diseases
1
Lymphoid Interstitial Pneumonia
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Lichen Planus
1
Leukokeratosis, Hereditary Mucosal
1
Klatskin Tumor
1
Fanconi Anemia
1
Erythroplasia
1
Colonic Polyps
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Transitional Cell
1
Interventions
Irinotecan
4
Oxaliplatin
3
Bevacizumab
3
trimebutine 3-thiocarbamoylbenzenesulfonate
2
pembrolizumab
2
Leucovorin
2
Fluorouracil
2
Cyclophosphamide
2
Cetuximab
2
Capecitabine
2
Aspirin
2
repotrectinib
1
pralsetinib
1
napabucasin
1
ibrutinib
1
guadecitabine
1
encorafenib
1
alectinib
1
XELOX
1
Sutures
1
Surgical Instruments
1
Optical Imaging
1
Ocoxin
1
Levoleucovorin
1
KRN-330
1
Drug Therapy
1
Control Groups
1
Ascorbic Acid
1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Colonic Diseases
×
Optical Imaging
×
Clear all
NCT03139942
2019-04-16
OPTIC
Imperial College London
Phase NA
Completed
13 enrolled